Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

4(40.0%)

Phase 2

4(40.0%)

Phase 1

2(20.0%)

10Total

Phase 3(4)

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02778399Phase 2Completed

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Role: lead

NCT03758885Phase 3Completed

Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF

Role: lead

NCT03070899Phase 3Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Role: lead

NCT03369262Phase 2Unknown

PoC Study of OBE022 in Threatened Preterm Labour

Role: lead

NCT03070951Phase 3Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Role: lead

NCT03961932Phase 1Completed

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Role: lead

NCT03962049Phase 1Completed

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Role: lead

NCT03081208Phase 3Completed

Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI

Role: lead

NCT02326142Phase 2Terminated

A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth

Role: lead

NCT02310802Phase 2Completed

OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI

Role: lead

All 10 trials loaded